跳至主要内容
临床试验/IRCT201112125280N7
IRCT201112125280N7已完成3 期

The Efficacy of ondansetron augmentation in negative sign of Schizophrenia

Mashhad University of Medical Sciences0 个研究点目标入组 44 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • patients who have been treated with a stable dose of risperidone as their primary antipsychotic treatment for a minimum period of 8 weeks before entry into the study.
  • Exclusion criteria: Patients who had any medical diagnoses (including ECG conduction abnormalities, neurological disorder, or an active seizure) or were receiving medications that may have affected cognitive performance; Subjects who met the criteria for a DSM IV diagnosis of alcohol or substance abuse (other than for nicotine) within the last month or the criteria for DSM-IV alcohol or substance dependence (other than for nicotine) within the last 6 months; Pregnant or lactating women and those of reproductive age without adequate contraception; psychotropic medications were not allowed for the duration of the study: anticholinergics, sedating antihistaminic, antidepressants, mood stabilizers, or a second antipsychotic (as adjuvant therapy).

排除标准

  • 未提供

研究者

相似试验

The Efficacy of ondansetron augmentation in negative... | 临床试验